Anti-EGFR re-challenge with chemotherapy in RAS wild-type advanced colorectal cancer (A-REPEAT study): efficacy and correlations with tissue and plasma genotyping.

(the CAVE study), where patients with tissue-based RAS wild-type tumours were treated with re-challenge panitumumab and the anti-programmed death-ligand 1 monoclonal antibody avelumab without chemotherapy, a post hoc analysis showed a trend of higher control of disease in patients with ctDNA RAS wild-type tissue versus non-wild-type tissue (73% versus 47%). 13 Finally, in a pooled analysis of individual-patient data from the four Italian studies CRICKET, CAVE, CHRONOS and VELO, analysing only patients with liquid RAS/BRAF wild-type tu

also in 53,322 other papers